Geoff Meacham analyst BAML

Currently out of the existing stock ratings of Geoff Meacham, 182 are a BUY (59.48%), 96 are a HOLD (31.37%), 28 are a SELL (9.15%).

Geoff Meacham

Work Performance Price Targets & Ratings Chart

Analyst Geoff Meacham works at BAML with a stock forecast success ratio of 69.46% fulfilled within 215.8 days on average.

Geoff Meacham’s has documented 590 price targets and ratings displayed on 51 stocks. The coverage is on Healthcare, Technology sectors.

Most recent stock forecast was given on BTAI, BioXcel Therapeutics at 13-Mar-2024.

Wall Street Analyst Geoff Meacham

Analyst best performing recommendations are on OMER (OMEROS).
The best stock recommendation documented was for PTCT (PTC THERAPEUTICS) at 8/8/2018. The price target of $43 was fulfilled within 1 day with a profit of $2.28 (5.6%) receiving and performance score of 55.99.

Average potential price target upside

ALXN Alexion Pharmaceuticals AMGN Amgen BIIB Biogen BMRN Biomarin Pharmaceutical BMY Bristol-Myers Squibb Company BTAI BioXcel Therapeutics CMPI Checkmate Pharmaceuticals CVAC CureVac NV GILD Gilead Sciences IIVI II-VI orporated INCY yte INO Inovio Pharmaceuticals JNJ Johnson & Johnson LLY Eli Lilly and Company MRK Merck mpany MRNA Moderna PFE Pfizer REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals KNSA Kiniksa Pharmaceuticals Ltd PMVP Pmv Pharmaceuticals  PTCT PTC Therapeutics SGEN Seagen ABBV AbbVie ARAV Aravive CELG Celgene KYMR Kymera Therapeutics NBIX Neurocrine Biosciences ABOS Acumen Pharmaceuticals UTHR United Therapeutics VAXX Vaxxinity XLRN Acceleron Pharma ALNY Alnylam Pharmaceuticals ACHN Achillion Pharmaceuticals BBIO BridgeBio Pharma CMRX Chimerix CRBU Caribou Biosciences CRSP Crispr Therapeutics AG GRPH Graphite Bio ICPT Intercept Pharmaceuticals IPSC Century Therapeutics MYOV Myovant Sciences Ltd OMER Omeros PRTA Prothena plc RPRX Royalty Pharma Plc RTRX Travere Therapeutics TYRA Tyra Biosciences IGMS IGM Biosciences RANI Rani Therapeutics Holdings VIR Vir Biotechnology LIAN LianBio ADR

Analyst name

Rating

Current price target

Potential distance

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

205

$22.5 (12.33%)

2 years 11 months 7 days ago

3/5 (60%)

$35.09 (20.65%)

938

Hold

173

$-9.5 (-5.21%)

156

2 years 11 months 9 days ago

14/24 (58.33%)

$2.73 (1.60%)

682

Hold

190

$7.5 (4.11%)

194

3 years 2 months 8 days ago

9/11 (81.82%)

$34.41 (22.12%)

350

Hold

166

$-16.5 (-9.04%)

175

3 years 2 months 8 days ago

23/23 (100%)

$10.41 (6.69%)

828

Buy

155

3 years 3 months 5 days ago

7/7 (100%)

$36.79 (31.12%)

395

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Geoff Meacham is most bullish on?

Potential upside of $222.71 has been obtained for LLY (ELI LILLY AND COMPANY)

Which stock is Geoff Meacham is most reserved on?

Potential downside of -$628.14 has been obtained for LIAN (LIANBIO ADR)

What Year was the first public recommendation made by Geoff Meacham?

On 2012

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?